Get notified when SNTI files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SNTI Senti Biosciences Holdings, Inc. 8-K

Senti Biosciences reports Q1 2026 results, announces SENTI-202 clinical and regulatory update

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

Key Changes

  • medium

    Company disclosed clinical data and regulatory interactions for SENTI-202, its product in development. Specific details on trial outcomes or FDA feedback are in the press release, signaling potential program progress.

    Item 8.01 verify on EDGAR →
  • medium

    Senti announced financial results for the quarter ended March 31, 2026. This is a routine quarterly earnings disclosure with detailed figures provided in the attached press release.

    Item 8.01 verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.

Partner

Trade SNTI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov Press release (Ex 99.1) on EDGAR ↗ Press release (Ex 99.2) on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify